Anti-vascular endothelial growth factor (VEGF) therapy is widely used to maintain visual functioning in macular diseases including diabetic macular edema (DME). We report a case of a hypertensive cerebral hemorrhage even after intravitreal injections of aflibercept for DME in which the patient’s plasma VEGF levels were below the detection limit.